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Performance of the G4 Xpert® MTB/RIF
assay for the detection of Mycobacterium
tuberculosis and rifampin resistance: a
retrospective case-control study of
analytical and clinical samples from high-
and low-tuberculosis prevalence settings
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Abstract
Background: The Xpert® MTB/RIF (Xpert) assay is a rapid PCR-based assay for the detection of Mycobacterium
tuberculosis complex DNA (MTBc) and mutations associated with rifampin resistance (RIF). An updated version
introduced in 2011, the G4 Xpert, included modifications to probe B and updated analytic software.
Methods: An analytical study was performed to assess Xpert detection of mutations associated with rifampin
resistance in rifampin-susceptible and -resistant isolates. A clinical study was performed in which specimens from
US and non-US persons suspected of tuberculosis (TB) were tested to determine Xpert performance characteristics.
All specimens underwent smear microscopy, mycobacterial culture, conventional drug-susceptibility testing and
Xpert testing; DNA from isolates with discordant rifampin resistance results was sequenced.
Results: Among 191 laboratory-prepared isolates in the analytical study, Xpert sensitivity for detection of rifampin
resistance associated mutations was 97.7% and specificity was 90.8%, which increased to 99.0% after DNA
sequencing analysis of the discordant samples. Of the 1,096 subjects in the four clinical studies, 49% were from the
US. Overall, Xpert detected MTBc in 439 of 468 culture-positive specimens for a sensitivity of 93.8% (95% confidence
interval [CI]: 91.2%–95.7%) and did not detect MTBc in 620 of 628 culture-negative specimens for a specificity of 98.
7% (95% CI: 97.5%–99.4%). Sensitivity was 99.7% among smear-positive cases, and 76.1% among smear-negative
cases. Non-determinate MTBc detection and false-positive RIF resistance results were low (1.2 and 0.9%,
respectively).
Conclusions: The updated Xpert assay retained the high sensitivity and specificity of the previous assay versions
and demonstrated low rates of non-determinate and RIF resistance false positive results.
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Background
The Xpert® MTB/RIF (Xpert) assay [1, 2] detects the
presence of Mycobacterium tuberculosis complex DNA
(MTBc) and mutations associated with resistance to
rifampin (RIF) in clinical samples in under two hours.
Xpert was endorsed by the World Health Organization
(WHO) in December 2010 [2, 3] and recent meta-
analyses describe the assay’s excellent performance
characteristics in the field [4, 5]. Since the release of
Xpert for use, several modifications have been made to
improve assay performance. The updated version, the
G4 Xpert, includes modifications to one of the five
rpoB-specific assay probes (probe B) and to the analytic
software settings with the goal of decreasing both false
positive RIF resistance results and the >5% non-
determinate result rate reported in some settings [6].
Although the updated G4 Xpert assay was available for
use in December 2011 [6], most published Xpert
performance reports were conducted using previous
versions of the assay [4]. In addition, few studies have
reported the performance of the G4 Xpert on samples
from both high- and low-tuberculosis (TB) prevalence
populations. Here we present data on G4 Xpert assay
performance from analytical testing and multi-site
clinical studies in various settings, including settings
with a low prevalence of TB.
Methods
Study design and specimen inclusion criteria
Analytical testing of rifampin resistance detection
performance
Xpert performance of RIF resistance detection was
evaluated using 200 unique clinical isolates spiked into
pooled human sputum. The isolates were selected from
the specimen bank at the Massachusetts Supranational
Tuberculosis Reference Laboratory at the University of
Massachusetts Medical School and had been obtained
from standard of care (SOC) sputum specimens from in-
dividuals in Russia, Peru, Hong Kong, Haiti, and USA.
Isolates were selected based on phenotypic drug suscep-
tibility test results. One hundred RIF susceptible isolates,
100 RIF resistant isolates and an additional 50 aliquots
of MTB culture-negative pooled human sputum were
randomized and blinded for testing.
Clinical studies
Four clinical studies were conducted to assess Xpert
detection of MTBc and RIF resistance in specimens
from patients 18 years of age or older with suspected
TB. Clinical study 1 (CS1) included four collections of
archived MTB culture-positive and -negative specimens
collected from non-US regions as part of research studies
conducted by the Foundation for Innovative New
Diagnostics [7]. Subject inclusion criteria were: 1)
pulmonary TB symptoms (see Additional file 1); and 2) no
anti-TB medication in the 60 days prior to sample collec-
tion. Xpert testing was performed at New Jersey Medical
School (NJMS).
Clinical study 2 (CS2) specimens consisted of archived
MTB culture-positive and culture-negative sputum
specimens that were leftover from SOC evaluations of
US patients with suspected TB illness. Xpert testing was
done at the State of New York Department of Health in
Albany, NY.
Clinical study 3 (CS3) and 4 (CS4) tested up to three
prospectively collected leftover SOC specimens from US
(CS3) and Mexican (CS4) patients suspected to have TB;
the first specimen with sufficient volume was selected for
Xpert testing. CS3 Xpert testing was done at the New
York State Department of Health in Albany, NY, the
Florida Department of Health, Bureau of Public Health
Laboratories in Jacksonville, FL, and the Orange County
Health Care Agency in Santa Ana, CA. CS4 Xpert testing
was performed at the Orange County Health Care Agency
in Santa Ana, CA.
See Additional file 1 for further details on study design
and specimen inclusion criteria.
Laboratory testing
In the analytical study, culture-positive isolates were con-
firmed to be MTBc positive by AccuProbe MTBC Identifi-
cation Test (Hologic Incorporated, Marlborough, MA).
Rifampin susceptibility was determined via the Middleb-
rook agar proportion method [8] according to each
laboratory’s standard operating procedure. Bi-directional
sequencing of the rpoB core region was performed for all
specimens with discordant RIF resistance results. The cul-
ture isolates were spiked at low, moderate, or high con-
centrations into sputa (see Additional file 1) and tested
with the Xpert assay. Fifty aliquots of pooled MTB nega-
tive human sputum were interspersed randomly during
testing as a negative control.
The methods used at each of the clinical study sites
for AFB smear, MTB culture, and DST are summarized
in Table 1. Samples in all studies were tested by Xpert
according to the package insert instructions [9]. All fro-
zen specimens were stored at -70 °C and all prospect-
ively collected samples were stored per the sample
storage constraints described in the package insert. If
multiple samples from each patient were available, the
first specimen with sufficient volume for testing was
used. Duplicate specimen enrollment for the same pa-
tient for Xpert testing was not allowed. Bi-directional se-
quencing of the rpoB core region was performed on
MTB culture-positive isolates with discordant Xpert
MTB or RIF susceptibility results. No sequencing was
performed for MTB culture-negative specimens with
discordant Xpert results. Sequencing of concordant
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Table 1 AFB smear, culture, TB identification and DST methods for each clinical study
Study number Geographical location/
collection site
Xpert MTB/RIF Assay
Testing Site
Specimen Used for Xpert
MTB/RIF Assay Testinga
Specimen Processing
for Smear & Culture
AFB Smear Method on
Processed Sputuma
Culture Methoda TB Identification
Methoda
DST Methoda
CS1 Peru NJMS Archived
(Frozen)
Raw Sputum NALC-NaOH ZN LJ and MGIT CapilliaTB-Neo LJ Proportions
South Africa, Vietnam,
Bangladeshb,c
NJMS Archived
(Frozen)
Raw Sputum NALC- NaOH ZN LJ and MGIT GenoType®
MTBC
MGIT SIRE
CS2 New York New York Archived
(4 °C)
Pellet NaOH ZN 7H10 and MGIT In house RT-PCR MB Proportions
CS3 New York New York Fresh Pellet NaOH ZN 7H10 and MGIT In house RT-PCR MB Proportionsd
California California Fresh Pellet NALC- NaOH AuRho 7H10 and MGIT AccuProbe MTBC MB Proportionsd
Florida Florida Fresh Pellet or
Raw Sputum
NALC-NaOH AccuProbe MB Proportionsd
AuO + ZN LJ and MGIT AccuProbe MTBC
CS4 Tijuana, Mexico California Fresh Raw Sputum NALC-NaOH AuRho LJ and MGIT AccuProbe
MTBCe
MB Proportionse
aZN Ziehl-Neelsen, AuRho Auramine Rhodamine, AuO Auramine O, Raw Sputum direct, not decontaminated/undigested, Pellet decontaminated/digested sediment, MB Middlebrook, LJ Lowenstein-Jensen, MGIT BD
BBL™ MGIT™ Mycobacteria Growth Indicator Tube, OADC Enrichment, PANTA™ Antibiotic Mixture, (Becton, Dickinson and Company, Sparks, MD), AccuProbe MTBC Mycobacterium tuberculosis Complex Culture
Identification Test (Hologic, Incorporated, Marlborough MA), MGIT SIRE BD BACTEC™ MGIT™ 960 SIRE Kits For the Antimycobacterial Susceptibility Testing of Mycobacterium tuberculosis, (Becton, Dickinson
and Company, Sparks, MD), Capillia TB-Neo Capilia TB Test Kit (Tauns Laboratories, Numazu, Japan), PNB – p-nitrobenzoic acid, Genotype® MTBC GenoType® MTBC (Hain Lifescience GmbH, Nehren, Germany)
bSpecimens were originally cultured and identified for MTB using the following methods: Capillia TB-Neo, Hain Genotype, Niacin + PNB5 at these sites: Unit for Clinical and Biomedical TB Research, South African
Medical Research Council. Durban, South Africa, Pham Ngoc Thach Hospital Laboratory. Ho Chi Minh City, Vietnam, Bangladesh: International Centre for Diarrhoeal Disease Research, Bangladesh. Dhaka, Bangladesh.
Raw frozen sputum specimens were available and sent to the National Reference Center (NRC) for Mycobacteria, Supranational Reference Laboratory (SRL) of WHO, Research Center Borstel - Leibniz Center for Medicine
and Biosciences, Borstel Germany for culture confirmation and DST and when appropriate bi-directional sequencing
cSamples were provided by the Foundation for Innovative Diagnostics (FIND) under their study protocol. FIND staff performed all of the data collection, monitoring and auditing of the study
dNew York served as the central lab for DST testing and, when appropriate, for bi-directional sequencing
eUniversity of Massachusetts Medical School served as the central lab for CS4 TB identification and DST testing
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samples was omitted. Sequencing was performed in Bor-
stel Germany for CS1, at the NY State Department of
Health for CS2 and CS3, and at the University of Massa-
chusetts Medical School for CS4.
Clinical study case definitions
AFB smear status was determined using the specimen
with a corresponding Xpert result. An MTB positive
case was defined as MTB growth on solid or liquid
culture from any specimen. An MTB negative case was
defined as no MTB growth from any baseline specimen;
baseline was defined as collected within seven days of
presentation. A case was defined as MTB indeterminate
when all cultures were overgrown by non-MTB bacteria
or fungi and an MTB positive or negative culture result
could not be determined. Phenotypic resistance was de-
termined to be present if 1% or more of the test popula-
tion grew in the presence of the critical concentration of
rifampicin, defined as 1.0 μg/mL.
The GeneXpert software (Version 4.3) reported MTB
results as “MTB detected” or “MTB not detected” and
RIF resistance results as “MTB detected; RIF resistance
detected”, “MTB detected; RIF resistance not detected”,
and “MTB detected; RIF resistance indeterminate”.
Xpert results of “invalid”, “error” or “no result” were
defined as “non-determinate”.
Statistical analysis
Xpert detection of MTBc DNA was assessed relative to
culture; culture indeterminate and Xpert non-determinate
specimens were excluded. Xpert detection of mutations
associated with RIF resistance was assessed relative to
DST; specimens where DST results were not available,
MTBc was not detected by Xpert, or MTBc was detected
but RIF resistance results were indeterminate were ex-
cluded. See Additional file 1 for further details including
sample size calculations.
For the clinical studies, any specimens involved in
protocol deviations were excluded from analysis (see
Figs. 1, 2 and 3). Specimens in CS1 were collected from
subjects participating in a research study and specimens
tested in CS2-4 were SOC specimens. Data from the
four clinical studies were tested for homogeneity across
multiple parameters using the Fisher’s Exact Test. A
critical p-value was set to 0.01 due to multiple testing in
several categories (Bonferroni principle).
Results
Specimen inclusion and clinical demographics
Analytical study
Of the 200 culture-positive isolates from the specimen
bank at the Massachusetts Supranational TB Reference
Laboratory identified for inclusion in this study, nine
were excluded due to: no culture growth (n = 4);
specimen was not inoculated on LJ media (n = 4); speci-
men was lost (n = 1); and specimen was from a duplicate
subject (n = 1). Of the remaining 191, 118 (62%) were
from Peru, 64 (34%) were from the U.S., 8 (4%) were
from Russia, and one was from an unknown WHO
collection site. No other demographic information was
collected for this study.
Clinical studies
A total of 1,026 specimens were obtained in the four
collections of specimens included in CS1. After the 400
specimens in collection two were excluded due to
544 Eligible Specimens
13 Excluded Specimens
Xpert assay results non-determinate (n=13)
531 Subjects Included in Data Analyses
626 Identified Specimens
82 Ineligible Specimens: 
MTB culture positivity not confirmed at central laboratory (n=80)
Quantity not sufficient (n=2)
Fig. 1 Clinical study 1 specimen accountability
92 Eligible Specimens
0 Excluded Specimens
92 Subjects Included in Data Analyses
100 Identified Specimens
8 Ineligible Specimens:
Duplicate subject (n=3)
Previous TB diagnosis (n=2)
TB treatment >2 days prior to enrollment (n=2)
Specimen processed outside time limit (n=1)
Fig. 2 Clinical Study 2 specimen accountability
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insufficient volume, 626 total specimens remained; of
these, 544 were eligible for Xpert testing (Fig. 1). Among
these, 358 (66%) were from males and 183 (34%) were
from females; the gender of the patient was unknown
for three specimens. The average age of the patient at
the time of specimen collection was 38 years (range 18-
83 years). Two hundred and eighty-eight (53%) patients
were from Vietnam, 174 (32%) were from Peru, 79 (15%)
were from South Africa, and 3 (0.6%) were from
Bangladesh. Thirteen specimens were excluded because
Xpert results were non-determinate, resulting in 531
available for inclusion.
Of 100 specimens identified for CS2, 92 were eli-
gible for inclusion in this analysis (Fig. 2). Of these,
51 (55%) were from males, 37 (40%) were from fe-
males and the gender of the patient was unknown for
4 (4%). The average age of the patient at the time of
specimen collection was 52.6 years (range 18 to
91 years).
CS3 and CS4 were analyzed separately and subse-
quently combined because specimens in both studies
were collected and tested prospectively. Of the 621 sub-
jects initially enrolled (592 in CS3 and 29 in CS4), 473
specimens were eligible for inclusion in the analysis
(Fig. 3). Of the enrolled subjects, 274 (60%) were male
and 185 (40%) were female; gender was unknown for 14.
The age of the subject was known for 118 (24.9%) of
study participants; of these, the average age at speci-
men collection was 52.4 years (range 19 to 88 years).
Forty-eight percent (n = 227) of the specimens were
from California, 25% (n = 118) were from New York,
22% (n = 105) were from Florida, and 5% (n = 23)
were from Mexico.
HIV status was either negative or not captured in the
clinical studies.
Xpert performance
Analytical study
Of the 191 clinical isolates, 185 were from Xpert
positive specimens, four were from MTB not detected
specimens, and two were from specimens reported as
non-determinate. Xpert reported RIF resistance in 85
of 87 isolates that were RIF resistant by DST for a
sensitivity of 97.7% (95% CI: 92.0%-99.4%). The Xpert
assay was negative for RIF resistance in 89 of 98
specimens that were RIF susceptible by DST for a
specificity of 90.8% (95% CI: 83.5%-95.1%). There
were no Xpert RIF indeterminate results. The rpoB
core region was sequenced for all 15 isolates with dis-
cordant Xpert results (Table 2a); Xpert reported RIF
resistance in all cases where there was a mutation in
the rpoB core region associated with RIF resistance
and in one case where there was not. Using resistance
associated rpoB core region mutations to define RIF
resistance, Xpert sensitivity for RIF resistance in-
creased to 97.7% (95% CI: 92.0%-99.4%) and specifi-
city to 99.0% (95% CI: 94.4%-99.8%).
477 Eligible Specimens
27 Excluded Specimens
Culture contaminated (n=14)
Xpert performed more than 7 days after sample collection (n=13)
450 Subjects Included in Data Analyses
621 Enrolled Subjects
115
115 Ineligible Subjects
Duplicate subjects (n=45)
Ineligible specimen type (n=32)
TB treatment more than two days prior to enrollment (n=16) 
Previous TB diagnosis (n=13)
Less than 18 years of age (n=6)
Received >7 days after collection (n=2)
Subject information unavailable (n=1)
28 Eligible Specimens
5 Excluded Specimens
Culture contaminated (n=3)
Quantity not sufficient (n=2)
23 Subjects Included in Data Analyses
1 Ineligible Specimen
TB treatment >2 days prior to enrollment
CS3
592 Enrolled Subjects
CS4
29 Enrolled Subjects
Fig. 3 Clinical Studies 3 and 4 specimen accountability
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Clinical studies
The results for all four clinical studies were analyzed
together across multiple parameters (see Additional file
1 for results of CS1 alone and poolability analysis).
Subject demographics
Among 1,096 subjects for which MTB culture results were
available, 679 (62%) were male and 396 (36%) were female;
gender was unknown for 21 (2%). The subjects were from
geographically diverse regions: 542 (49%) were from the US
(California, New York and Florida) and 554 (51%) were
from outside the US (Vietnam, Peru, South Africa, Mexico
and Bangladesh). Of the 542 US specimens, 450 (83%) were
collected prospectively and 92 (17%) were from an archived
specimen bank; of the 554 non-US specimens, 23 (4%) were
prospectively collected and 531 (96%) were from an ar-
chived specimen bank. One sputum specimen was collected
from 34% of subjects, two from 44%, and 3 from 22%. An
Xpert result was obtained with the first specimen collected
for 86% of subjects, with the second for 11% of subjects,
and with the third for 0.3% of subjects; for 3% of specimens
it was unknown which sputum was used for Xpert testing.
Xpert assay performance for detection of MTB
Overall, Xpert detected MTBc in 439 of 468 total speci-
mens that were culture positive for MTB for a sensitivity
of 93.8% (95% CI: 91.2%-95.7%). Xpert did not detect
MTBc in 620 of 628 culture-negative specimens for a
specificity of 98.7% (95% CI: 97.5%-99.4%). Among smear-
positive, culture-positive cases, Xpert detected MTBc in
350 of 351 cases for a sensitivity of 99.7% (95% CI: 98.4%-
99.9%). Among smear-negative, culture-positive cases,
Xpert detected MTBc in 89 of 117 cases for a sensitivity
of 76.1% (95% CI: 67.6%-82.9%). Discordant results are
presented in Table 2b.
Among US specimens (low prevalence settings), Xpert
sensitivity for detection of MTBc was 91.0% (95% CI:
83.3%-95.4%; n = 89) and specificity was 99.3% (95% CI:
98.1%-99.9%; n = 453). Among non-US specimens (high
prevalence settings), Xpert sensitivity for detection of
MTBc was 94.5% (95% CI: 91.7%-96.3%; n = 379) and speci-
ficity was 97.1% (95% CI: 93.5%-98.8%; n = 175). Xpert per-
formance characteristics for detection of MTBc are
stratified by sample collection method (535 expectorated,
234 induced, 327 unknown) and type of specimen (606
specimens were raw and 490 were concentrated) in Table 3.
Table 2 Sequence results for discrepant samples
a. Analytical study
DST Result Xpert MTB/RIF assay result Number Sequence resulta
RIF-resistant MTB not detected 3 MTB
RIF-susceptible MTB not detected 1 MTB
RIF-resistant RIF Resistance not detected 2 2 of 2 wild type rpoB core
RIF-susceptible RIF Resistance detected 9 8 of 9 with resistance associated mutations in rpoB core:
three with 531 ttg, three with 526 tgc, one with 516 gtc,
one with 526 ctc 1 of 9 wild type rpoB core
b. Combined clinical studies
Culture/DST result Xpert MTB/RIF assay result Number Bi-directional sequencing
Smear-positive specimens
MTB positive MTB not detected 1 MTB
MTB negativeb MTB detected 1 N/A
Smear-negative specimens
MTB positive MTB not detected 28 MTB
MTB negativec MTB detected 7 N/A
Rifampin resistance results
MTB positive/RIF- resistant MTB detected; RIF Resistance NOT detected 1 Resistance associated mutation in rpoB core: 531 ttg
with evidence of wild type mixture
MTB positive/RIF- susceptible MTB detected; RIF Resistance detected 4 2 of 4 with resistance associated mutations
in rpoB core: both with 533 ccg
2 of 4 with susceptible associated
rpoB core: one wild-type and one 514 ttt (silent) mutation.
aCulture negativity was based on only one sputum specimen for this subject
bCulture negativity classification was based on one sputum specimen for three subjects, two sputum specimens for two subjects and three sputum specimens for
two subjects
cIt is noted that DST did not detect some common mutations associated with rifampin resistance that were identified by sequencing. Several studies have
demonstrated that testing the same strains with varying DST methodology can result in different rifampin resistance results [12, 23–25]
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Xpert assay performance for detection of RIF resistance
MTB positive culture isolates were tested for susceptibil-
ity to rifampin using DST and results were compared
with Xpert detection of mutations associated with RIF
resistance. Of the 1,096 subjects tested by Xpert, 1,082
were included in the analysis. Eight subjects that did not
have DST results were excluded. Six of 447 (1.3%, 95%
CI: 0.6%-2.9%) specimens that were positive for MTBc
and RIF resistance indeterminate by Xpert were also
excluded; one of 351 (0.3%, 95% CI: 0.01%-1.6%) smear-
positive specimens and five of 96 (5.2%, 95% CI: 2.2%-
11.6%) smear-negative specimens.
Of the 1,082 included samples, 627 were culture nega-
tive and did not have DST. Of 455 remaining, 21 were
RIF resistant and 434 were RIF susceptible by DST.
Among the 21 samples with RIF resistance by DST, two
were Xpert MTBc negative and one was MTBc detected,
RIF resistance not detected. Excluding Xpert MTBc
negative samples, Xpert detected mutations associated
with RIF resistance in 18 of 19 samples for a sensitivity
of 94.7% (95% CI: 75.4%-99.1%). Of 434 samples that
were RIF susceptible by DST, 26 were Xpert MTBc
negative. Excluding those, Xpert did not report RIF re-
sistance in 404 of 408 samples for a specificity of 99.0%
(95% CI: 97.5-99.6%). Four samples were determined to
be RIF susceptible by DST and RIF resistant by Xpert.
One was tested by Agar Proportions using LJ in Peru
and three were tested using MGIT SIRE (BD BACTEC™
MGIT™ 960 SIRE Kits For the Antimycobacterial
Susceptibility Testing of Mycobacterium tuberculosis):
one in South Africa and two in Vietnam.
Bi-directional sequencing was performed on all
isolates from culture-positive specimens with discrepant
results (Table 2b). The one Xpert false RIF-susceptible
sample was determined to contain a mixture of wild type
and mutant rpoB core region DNA by sequencing. Three
of the four apparent Xpert false RIF resistant samples
had rpoB core mutations. One of these three was a silent
mutation (514ttt) while the other two had rpoB core
mutations associated with clinically relevant resistance
Table 3 Xpert MTB/RIF Assay performance vs. MTB culture stratified by specimen collection method and specimen type
AFB Smear-positive subjects AFB Smear-negative subjects All samples
Specimen Collection Methoda
Expectorated Sputum (n = 535)
Sensitivity 99.6% (271/272)b 79.0% (75/95)c 94.3% (346/367)d
95% CI: 97.9 – 99.9% 95% CI: 69.7 – 85.9% 95% CI: 91.4 – 96.2%
Specificity 97.6% (164/168)b
95% CI: 94.0 – 99.1%
Induced Sputum (n = 234)
Sensitivity 100% (15/15)b 40.0% (4/10)c 76% (19/25)d
95% CI: 79.6 – 100% 95% CI: 16.8 – 68.7% 95% CI: 56.6 – 85.5%
Specificity 99.0% (207/209)b
95% CI: 96.6 – 99.7%
Specimen Type
Raw Sputum (n = 606)
Sensitivity 99.7% (285/286)b 79.4% (77/97)e 94.5% (362/383)b
95% CI: 98.0 – 99.9% 95% CI: 70.3 – 86.2% 95% CI: 91.8% - 96.4%
Specificity 97.8% (218/223)b
95% CI: 94.9 – 99.0%
Concentrated Sputum Sediment (n = 490)
Sensitivity 100% (65/65)b 60.0% (12/20)e 90.6% (77/85)b
95% CI: 94.4 – 100% 95% CI: 38.7 – 78.1% 95% CI: 82.5% - 95.2%
Specificity 99.3% (402/405)b
95% CI: 97.8 – 99.7%
aCollection method for 327 specimens was unknown
bp-value for difference > 0.1
cp-value for difference = 0.014
dp-value for difference = 0.004
ep-value for difference = 0.084
AFB acid fast bacteria
95% CI 95% confidence interval
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not always identified by phenotypic RIF susceptibility
testing [10–13]. Overall, four (0.9%) had false positive ri-
fampin resistance test results; if using sequencing based
mitigation, two (0.5%) had false positive rifampin resist-
ance test results.
Of 1,126 tested specimens, 17 were excluded from the
sensitivity and specificity analysis due to culture contam-
ination. However, all 17 specimens had valid Xpert
results on the first attempt and were included in the cal-
culated non-determinate rate. Of the 1,126 specimens,
24 were non-determinate for the following reasons: 17
probe check failures, two temperature being out of range,
two signal losses, one SPC failure, one syringe motion,
and one cartridge integrity. Of the 24 non-determinate, 11
were successful on repeat test and 13 were not repeated
due to low sample volume. Overall, 13 (1.2%, 95% CI:
0.7% to 2.0%) of 1,126 specimens had a non-determinate
Xpert result.
Positive predictive value (PPV) and negative predictive
value (NPV) for Xpert detection of MTB and RIF resistance
The likelihood that a positive test result is a true positive
will vary based on the prevalence of TB in the popula-
tion and whether the AFB smear is positive or negative.
A prospective clinical evaluation of Xpert in patients
suspected of active TB in the United States resulted in a
prevalence of 11.8% and a percentage of AFB-positive
smears among MTB culture positive subjects of
75.5%[14]. Hypothetical estimated PPV and NPV of
MTB detection using Xpert for different prevalence rates
of MTB are shown in Table 4. These calculations are
based on the overall sensitivity and specificity observed
in all four clinical studies (as above, sensitivity of 99.7%
for smear positive specimens, 76.1% for smear-negative
specimens and overall specificity of 98.7%).
Hypothetical estimated predictive values for the result
“MTB Detected, RIF Resistance DETECTED” for differ-
ent prevalence rates of MTB culture positive subjects
and different prevalence rates of RIF resistance among
MTB culture positive subjects are shown in Table 5.
These calculations are based on hypothetical prevalences
and the overall sensitivity and specificity of Xpert RIF
resistance detection observed in all four clinical studies
(sensitivity 94.7% and specificity of 99.0%). In the US
population with TB the prevalence of rifampin resistance
is approximately 1.8% [14].
Discussion
We found high G4 Xpert sensitivity and specificity for
detection of MTBc and RIF resistance in both analytical
and clinical specimens collected from TB culture posi-
tive and negative subjects from US and non-US settings.
Sensitivity for detection of MTBc in clinical samples was
99.7% among smear-positive specimens, 76.1% among
smear-negative specimens and specificity was 98.7%.
These results are very similar to the 2013 Cochrane
review which found sensitivity of 98% and 67% for smear
positive and smear negative specimens respectively, and
a pooled specificity of 98% among studies using prior
versions of the assay [4]. Xpert sensitivity and specificity
for RIF resistance detection was 94.7% and 99% respect-
ively in our combined clinical studies. This also com-
pared well to reports using prior Xpert versions (94%
and 98%, respectively [4]). In our analytical study, sensi-
tivity and specificity for RIF resistance detection was
97.7% and 90.8%, respectively. However, this changed to
97.7% and 99.0%, respectively, when DNA sequencing
was used as the reference method. Several recent stud-
ies have shown that some rpoB mutations are asso-
ciated with low-level RIF resistance that are not
detected by phenotypic testing, yet have poor clinical
outcomes equivalent to patients with high level RIF
resistance [10–13].
A small study by Sohn et al. [15] evaluated the diag-
nostic accuracy of both G4 and the previous version of
the Xpert assay using induced sputum samples from 502
subjects in Montreal, Canada. The overall sensitivity of
Xpert was very low: 11/25 (46%) overall, 6/7 (86%) for
smear-positive specimens, and 5/17 (29%) for smear-
negative specimens. Sensitivity of the G4 (5/15, 33%)
was observed to be lower than the previous version (6/
10, 60%), but this difference was not significant and was
not stratified by smear status. The authors hypothesized
that the lower sensitivity may have been related to lower
bacillary load at presentation. Another possibility is that
target bacilli may have been diluted by the saline used
for induction [16].
Table 4 Hypothetical Predictive Values of Xpert detection of
MTBc vs. MTB Culture
Prevalence
of MTB
culture
positive
Probability of MTB culture positive
among
Probability of MTB
culture negative
among
Xpert MTB
detected AFB
Smear Pos.
Xpert MTB
detected AFB
Smear Neg.
Xpert MTB not
detected
1% 82.9 14.4 99.9
2% 90.8 25.4 99.9
3% 93.7 34.1 99.8
4% 95.2 41.0 99.7
5% 96.2 46.8 99.7
10% 98.2 65.0 99.3
11.8% 98.5% 69.1% 99.2%
20% 99.2 80.7 98.5
40% 99.7 91.8 96.1
50% 99.8 94.4 94.2
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We observed a statistically significant decrease in
sensitivity among induced sputum samples compared to
expectorated sputum for AFB smear-negative subjects
(4/10 vs. 77/97; p-value <0.01), but not in smear positive
samples (15/15 induced, 285/286 expectorated). How-
ever, other studies have observed that induced sputum
samples had a higher diagnostic yield by culture [17]
and shorter times to positivity by MGIT [18].
Thirteen (1.2%) of 1,126 specimens had a non-
determinate Xpert result, which was lower than previ-
ously reported rates of >5% using earlier Xpert versions.
Four samples were determined to be RIF susceptible by
DST and RIF resistant by Xpert and three were deter-
mined to have RIF resistance-associated mutations in
the rpoB core region by bi-directional sequencing
although one was a non-resistance associated silent mu-
tation. This leads to a 0.94% (4/427) false positive rate,
or 0.47% (2/427) if using sequencing based mitigation.
There are several limitations to this study. First,
sample collection, processing, shipment, storage and
testing were done across various settings, which may
have introduced some variability to our data collec-
tion and sample processing methods. In particular,
one of the clinical studies was conducted as part of a
research study, while the others analyzed leftover
SOC specimens. For this reason the research clinical
study was analyzed separately (see Additional file 1)
and a poolability analysis was conducted to demon-
strate that the four clinical studies could be com-
bined. In addition, some specimens had been frozen
and stored prior to testing, which may have intro-
duced variability in testing results.
Conclusions
We found that the G4 Xpert assay had low rates of non-
determinate and false positive RIF resistance results that
were not consistent with previously reported rates
observed at some sites. In addition, we found high sensi-
tivity and specificity for MTBc and RIF resistance detec-
tion that compared well to the previous versions of the
assay [4]. Most published reports of Xpert assay per-
formance were conducted using the previous versions of
the assay; our findings represent one of the first large
studies reporting G4 Xpert assay performance and add
to the growing literature [19–22] in both high- and low-
TB prevalence settings.
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